Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$2.77 USD
-0.07 (-2.46%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.77 0.00 (0.00%) 6:20 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Brokerage Reports
Galectin Therapeutics Inc. [GALT]
Reports for Purchase
Showing records 41 - 60 ( 108 total )
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Galectin Cleans up Balance Sheet and Related Covenants to Better Attract Outside Parties
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Finalizing Phase 3 Plans in NASH Cirrhosis; 3Q Recap; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
IST Data Support Broad Activity and Benign Safety Profile of GR-MD-02; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
2Q Recap: Preparations Continue Toward Start of Phase 3 NASH Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
A Path Forward: Planning Phase 3 Protocol, After Positive FDA Meeting; Affirm Buy, Raise PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: Kick off EASL with NASH BASH Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NASH Weekly Newsletter: Launch of Our Monthly Clinicaltrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Healthcare -Join Us for Our Spring NASH Bash, with 18 NASH Companies and 6 KOLs
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Healthcare NASH Is Hot and NASH Cirrhosis Is Getting Hotter! Expert Call: Jan. 22 - 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
New Year, New Beginnings; Affirm Buy with Increased PT of $8
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: Who in the NASH Space Had The Best And Worst Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Landmark NASH-CX Study Shows First Ever Benefit in NASH Cirrhosis; Raise PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Let the Count Begin to NASH-CX Data Readout; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Data Catalyst Alert: Phase 2b NASH-CX Readout Likely Next Week; Raise PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E